Dear Colleagues,
This has been an unusually productive stretch for renal cell carcinoma (RCC) research, and the Third Quarter 2026 issue of Kidney Cancer Journal reflects that momentum. Between the follow-through from ASCO’s Genitourinary Cancers Symposium earlier this year and the full publication of several pivotal trials over the summer, our field is refining not just what works, but for whom, and at what cost in toxicity and quality of life. I want to use this space to walk through the developments I consider most consequential for practicing clinicians, and to explain how they shaped the content you will find in the pages that follow.
The Adjuvant Landscape Continues to Mature
Adjuvant therapy for high-risk resected clear cell RCC remains one of the most actively contested areas in our field. KEYNOTE-564 established single-agent pembrolizumab as a standard of care in the intermediate- to high-risk post-nephrectomy setting, and most of us have now accumulated several years of real-world experience applying it. The open question has been whether we can improve on that benefit, and at what price.
LITESPARK-022, which paired pembrolizumab with the HIF-2α inhibitor belzutifan in the adjuvant setting, has continued to generate discussion since its initial readout, and our Journal Club section this quarter revisits the trial with a sharper focus on the toxicity trade-off. The disease-free survival advantage over pembrolizumab alone is real, but so is the added burden of anemia, hypoxia, and other class-related adverse events. I have asked our contributors to address a question I hear constantly from colleagues in community practice: how do we counsel a patient who is already anxious about recurrence, when the incremental benefit must be weighed against a more demanding toxicity and monitoring profile? The Fox Chase Nomogram and other risk-stratification tools deserve more consistent use in this conversation, and you will see that argument made explicitly in this issue’s commentary.
LITESPARK-011 Reaches Full Publication
The full phase 3 results of LITESPARK-011, comparing belzutifan plus lenvatinib against cabozantinib in previously treated advanced RCC, were published this quarter. This trial matters because it tests a chemistry-free combination strategy in a treatment-refractory population that desperately needs new options after progression on immunotherapy and VEGFR-targeted therapy. Our research summary in this issue walks through the efficacy and safety data in detail, but the broader significance is this: belzutifan is moving from a niche VHL-disease and adjuvant-combination agent toward a more central role across multiple lines of RCC therapy. I expect this class of HIF-2α inhibitors to occupy an increasing share of our treatment algorithms over the next several editorial cycles, and I have asked our Around the Corner column to keep tracking where these agents are being tested next, including earlier lines and novel combinations.
Biology Catching Up With the Clinic
It is easy, in a quarter dominated by large randomized trials, to overlook the basic and translational science that will define our next decade of therapy. Several papers this quarter caught my attention. Work characterizing tertiary lymphoid structures in RCC tumors has strengthened the case that these structures are not incidental findings but active reservoirs of stem-like, tumor-specific CD8+ T cells, a finding with direct relevance to how we think about immunotherapy response and resistance. Separately, mechanistic work on mTOR inhibitor resistance, tied to ZMYND8 ubiquitination and phase-separation biology, adds another piece to the long-standing puzzle of why mTOR-targeted agents lose efficacy over time in clear cell disease. And a new integrative multi-omic analysis of RCC subtypes offers a broader map of the transcription factors and regulatory circuits driving tumor biology, work that will take years to translate but that our field needs if we are going to move past a treatment paradigm built primarily on VEGF and immune checkpoint blockade.
Novel Agents and Combinations in the Pipeline
This year’s ASCO GU meeting continues to reverberate through the abstracts and correspondence crossing my desk. Among the approaches I am watching most closely: the phase 2 IVORY trial of ivonescimab, a bispecific PD-1/VEGF antibody, in patients previously treated with checkpoint inhibitors; early combination work pairing radiolabeled girentuximab with cabozantinib and nivolumab in treatment-naive advanced clear cell RCC; and cellular approaches such as TANKeR-70, using TGF-β receptor knockout allogeneic NK cells against CD70-expressing tumors. None of these is close to changing standard practice today, but each represents a distinct mechanistic bet on how to extend benefit beyond our current checkpoint-inhibitor and TKI backbone, and our Journal is committed to tracking them through to maturity rather than covering them once and moving on.
A Note on Real-World Evidence
I also want to flag the continued output of real-world and health-related quality-of-life analyses building on CheckMate 9ER, including new work identifying which symptoms most affect patients on nivolumab plus cabozantinib relative to sunitinib. As adjuvant and combination regimens multiply, our obligation to patients extends beyond progression-free and overall survival curves. Quality-of-life data deserves the same editorial rigor we apply to efficacy data, and you will continue to see it represented in these pages.
In This Issue
Beyond the research summaries described above, this issue includes expert commentary from members of our editorial board, an expanded Journal Club critique of the LITESPARK-022 toxicity data, and our regular Around the Corner column surveying earlier-phase RCC studies worth watching over the next two quarters. As always, I am grateful to our reviewers and contributing authors for the care they bring to this work, often on a fast turnaround and without much public recognition.
Please do not hesitate to reach out directly with topics you believe deserve deeper coverage in future issues.
